The short version of LC-MS/MS fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-11-27 and is reviewed periodically as new material appears.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
Published literature on cardarine includes in vitro assays, rodent experiments, and a small number of human studies. Reports describe effects on exercise capacity and lipid metabolism in animals, while human evidence is sparse. Many online descriptions present the compound as a proven endurance aid, a claim not supported by regulatory approval or large clinical trials. Analytical studies focus on identifying the parent compound and its metabolites in biological samples. Important uncertainties include species differences, dose-response relationships, and the relevance of rodent tumor findings to humans.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
Because cardarine is not an approved medicine, no pharmacopeial monograph defines its identity, purity, or storage requirements. Laboratories typically rely on in-house methods and reference standards when testing materials labeled as GW501516. Certificates of analysis may report purity and identity for a specific batch, but their scope varies and they do not guarantee safety or legal status. Independent verification can include high-performance liquid chromatography, mass spectrometry, nuclear magnetic resonance, and elemental analysis. The distinction between research chemical labeling and human use is significant because quality standards and oversight differ.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Also called GW501516 and endurobol. |
| Chemical formula | C21H18F3NO3S2 | Molecular weight about 453.5 g/mol. |
| Appearance | White to off-white solid | Form depends on synthesis and purity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water. |
| Typical storage | -20 °C, desiccated, protected from light | Common for research chemicals. |
Literature on cardarine often separates receptor pharmacology from toxicology. Mechanistic papers describe PPARδ activation and gene expression changes, while safety assessments focus on carcinogenicity and species differences. Questions remain about whether rodent tumors arise through PPARδ-dependent or off-target mechanisms. Another open area is how human metabolism and exposure compare with those in animal studies. Analytical methods such as liquid chromatography–mass spectrometry are used to confirm identity in biological and product samples.
GW501516 acts as an agonist at the peroxisome proliferator-activated receptor delta, a nuclear receptor that regulates gene expression. Activation shifts transcription toward genes involved in fatty acid uptake, oxidation, and energy expenditure. The compound does not bind the androgen receptor and therefore differs from anabolic steroids and SARMs. In rodent models, this metabolic shift has been linked to increased running endurance and reduced fat accumulation. The exact downstream pathways in humans remain incompletely characterized.
Analytical laboratories typically identify cardarine and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is a common matrix in anti-doping testing, while blood and tissue may be used in research settings. Detection windows depend on the assay, the sample matrix, and the compound's metabolism. Because cardarine is extensively metabolized, laboratories often target specific metabolites to improve sensitivity and confirmation. Reference standards are required for reliable quantification. Method validation includes checks for selectivity, linearity, and carryover.
A persistent misconception is that cardarine is a fat-burning drug or a safe alternative to anabolic steroids. No approved therapeutic product exists, and human safety data are limited. The tumor findings in rodents remain a central concern in scientific reviews. Products sold online may contain inaccurate labels, impurities, or different compounds entirely, which complicates any assessment of effects. Independent testing of such products has reported frequent mislabeling. For these reasons, discussions in the literature emphasize risks and unknowns rather than benefits.
Cardarine is not approved for human therapeutic use in any major jurisdiction. It appears on the World Anti-Doping Agency Prohibited List as a PPARδ agonist within the hormone and metabolic modulators category. Sports organizations test for it because it has been detected in athlete samples and seized products. Regulatory actions against marketed research chemical versions have occurred in several countries, though enforcement varies. Availability through unregulated channels complicates oversight.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
== Lineage == Constituted 5 July 1942 in the Army of the United States as the 2d Company, 1st Battalion, First Regiment, 1st Special Service Force, a combined Canadian-American organization Activated on 9 July 1942 at Fort William Henry Harrison, Montana Disbanded on 6 January 1945 in France Reconstituted on 15 April 1960 in the Regular Army; concurrently consolidated with Company B, 1st Ranger Infantry Battalion (activated 19 June 1942), and consolidated unit redesignated as Headquarters and Headquarters Company, 1st Special Forces Group, 1st Special Forces Consolidated on 30 September 1960 with Headquarters and Headquarters Company, 1st Special Forces Group (constituted 14 June 1957 in the Regular Army and activated 24 June 1957 in Japan), and the consolidated unit was designated as Headquarters and Headquarters Company, 1st Special Forces Group, 1st Special Forces (organic units concurrently constituted and activated 4 October 1960) Group inactivated 30 June 1974 at Fort Bragg, North Carolina Activated 1 September 1984 at Fort Lewis, Washington (Former Company B, 1st Ranger Infantry Battalion, withdrawn 3 February 1986, consolidated with Company N, 75th Infantry, and consolidated unit redesignated as Company N, 75th Ranger Regiment – hereafter separate lineage) Redesignated 1 October 2005 as the 1st Special Forces Group, 1st Special Forces Regiment
==== Metabolism ==== Mephedrone undergoes extensive metabolism, primarily through the cytochrome P450 2D6 (CYP2D6) enzyme. The main phase I metabolic pathways include N-demethylation, reduction of the ketone moiety, and oxidation of the tolyl group. Key metabolites identified in human plasma and urine include nor-mephedrone, dihydro-mephedrone, hydroxytolyl-mephedrone, and 4-carboxy-mephedrone, with 4-carboxy-mephedrone being the most abundant. Based on the analysis of rat and human urine by gas chromatography and mass spectrometry, mephedrone is thought to be metabolised by three phase 1 pathways. It can be demethylated to the primary amine (producing compounds 2, 3 and 5), the ketone group can be reduced (producing 3), or the tolyl group can be oxidised (producing 6). Both 5 and 6 are thought to be further metabolised by conjugation to the glucuronide and sulfate derivatives. Knowledge of the primary routes of metabolism should allow the intake of mephedrone to be confirmed by drug tests, as well as more accurate determination of the causes of side effects and potential for toxicity.
Biomaterials are used in: Joint replacements Bone plates Intraocular lenses (IOLs) for eye surgery Bone cement Artificial ligaments and tendons Dental implants for tooth fixation Blood vessel prostheses Heart valves Skin repair devices (artificial tissue) Cochlear replacements Contact lenses Breast implants Drug delivery mechanisms Sustainable materials Vascular grafts Stents Nerve conduits Surgical sutures, clips, and staples for wound closure Pins and screws for fracture stabilisation Surgical mesh Biomaterials must be compatible with the body, and there are often issues of biocompatibility, which must be resolved before a product can be placed on the market and used in a clinical setting. Because of this, biomaterials are usually subjected to the same requirements as those undergone by new drug therapies. All manufacturing companies are also required to ensure traceability of all of their products, so that if a defective product is discovered, others in the same batch may be traced.
When an 235U atom captures a neutron, it is converted to an excited state of 236U. About 85.5% of the excited 236U nuclei undergo fission, but the remainder decay to the ground state of 236U by emitting gamma radiation. Further neutron capture forms 237U which has a half-life of 7 days and quickly decays to 237Np through beta decay. During beta decay, the excited 237U emits an electron, while the atomic weak interaction converts a neutron to a proton, thus creating 237Np.
Tin-126 is a radioisotope of tin and one of the only seven long-lived fission products. While tin-126's half-life of 230,000 years means a relatively low specific activity, its short-lived decay products, two isomers of antimony-126, emit a cascade of hard gamma radiation - at least 3 photons above 400 keV per decay - before reaching stable tellurium-126, making it a possible external exposure hazard, which the other long-lived fission products are not by comparison. Tin-126 is in the middle of the mass range for fission products, so its yield is fairly low (but still dominates that for the element tin). Fission of the common fuels such as 235U and 239Pu into unequal halves is preferred, especially with thermal neutrons, as used in almost all current nuclear power plants.
Sources: en.wikipedia.org
The best-characterized reference (“type”) strain of S. boulardii is CBS 5926, which is also deposited under the culture collection numbers ATCC 74012 and CNCM I-745. This strain dominates commercial use of S. boulardii and is produced by the pharmaceutical company Biocodex; it has been evaluated in more than 90 randomized clinical trials. In addition to CNCM I-745, several manufacturers market S. boulardii supplements derived from distinct, often proprietary strains, including CNCM I-1079, CNCM I-3799, and DBVPG 6763, although it remains unclear whether it is genetically identical to CBS 5926.
Amorpha-4,11-diene 12-monooxygenase (EC 1.14.14.114, CYP71AV1) is an enzyme with systematic name amorpha-4,11-diene,NADPH:oxygen oxidoreductase (12-hydroxylating). This enzyme catalyses the following overall chemical reaction
=== Entrepreneurship and biotechnology investing === Springer co-founded biotechnology companies Scholar Rock in 2012, Morphic Therapeutic in 2015, Tectonic Therapeutic in 2019, and Seismic Therapeutic in 2022. He was also an early investor in Selecta Biosciences and Editas Medicine. Springer was a founding investor of Moderna after investing USD$5 million in 2010. He was the company's fourth-largest shareholder and made USD$400 million when the company launched its initial public offering (IPO) in 2018. During the COVID-19 pandemic, Forbes estimated Springer's net worth as USD$1 billion after in share price of biotechnology companies surged.
=== Aliens: Colonial Marines === Aliens: Colonial Marines was a result of Gearbox's exploration into working on licensed film properties in 2007, and was developed under license from 20th Century Fox, who held the film rights, and Sega, who held the game publishing rights to the franchise. Aliens: Colonial Marines was planned as a first-person shooter, both single-player and multiplayer, with players as members of human squads facing the franchises titular xenomorphs in settings based on the films. Gearbox did initial development on the game, but as the studio started working on Borderlands and Duke Nukem Forever, they drew developers off Aliens though still collected full payments from Sega. Sega and 2K discovered the discrepancy on Gearbox's allocation of its staff on its projects, which lead to a round of layoffs in 2008. After Gearbox released Borderlands to critical acclaim in 2009, it began work on its sequel rather than re-allocating developers to Aliens. Instead, the studio outsourced the work to third parties, including Demiurge Studios, Nerve Software, and TimeGate Studios. By 2012, Gearbox took over full development of the game as it neared its planned release in February 2013, but due to the heavily outsourced process, the game's state was haphazard, forcing Gearbox to cancel a planned beta period and rush the game through the final stages of production, certification, and distribution.
=== Halide addition === Ethylene oxide readily reacts with aqueous solutions of hydrochloric, hydrobromic, and hydroiodic acids to form halohydrins. The reaction occurs easier with the last two acids:
Sources: en.wikipedia.org
Norman Geras (25 August 1943 – 18 October 2013); political theorist of Rhodesian Jewish origin; Professor Emeritus of Politics at the University of Manchester; author of over ten scholarly and historical texts, mostly focused on radical politics; contributed to analysis of Karl Marx in Marx and Human Nature; in 2006, he was one of the principal authors of the Euston Manifesto. Martin Gilbert (25 October 1936 – 3 February 2015); historian and honorary Fellow of Merton College, Oxford; author of 88 books, including works on Winston Churchill, the 20th century, and Jewish history including the Holocaust; was a member of the Chilcot Inquiry into Britain's role in the Iraq War; noted for his endorsement of Bat Ye'or and Eurabia theory, providing comment for her book, stating that the theory "is 100 percent accurate". One of Gilbert's last books, In Ishmael's House: A History of the Jews in Muslim Lands cited Ye'or with approval several times. Morris Ginsberg FBA (14 May 1889 – 31 August 1970) British sociologist and prolific author who played a key role in the development of the discipline of sociology. He served as editor of The Sociological Review in the 1930s and later became the founding chairman of the British Sociological Association in 1951 and its first President (1955–1957). He was president of the Aristotelian Society from 1942 to 1943, and helped draft the UNESCO 1950 statement titled The Race Question.
The monocyte monolayer assay (MMA) is used to determine the clinical significance of alloantibodies produced by blood transfusion recipients. The assay is used to assess the potential for intravascular hemolysis when incompatible cellular blood products are transfused to the anemic patient. When donor cells possess substances that are not produced by the recipient, the recipient's immune system produces antibodies against the substance; these are called alloantibodies. Specific white blood cells, called monocytes, are tasked with ingesting foreign material and become activated during certain inflammatory events. These activated monocytes come in contact with antibody-sensitized red blood cells (RBC) and may or may not exhibit phagocytosis (ingestion) and destroy the donor red blood cells. If monocytes destroy the RBC, the antibody attached to those RBC is considered clinically significant.
Simulating the systemic environment in tectonic fault zones within the Earth's crust, pressure cycling forms vesicles periodically, as well as random peptide chains which are selected for ability to integrate into the vesicle membrane. Further selection of vesicles for stability could lead to functional peptide structures, increasing vesicle survival rate.
=== Surgery === On 12 June 1831, Dupuytren performed a surgical procedure on a person with contracture of the fourth and fifth digits who had been previously told by other surgeons that the only remedy was cutting the flexor tendons. He described the condition and the operation in The Lancet in 1834 after presenting it in 1833, and posthumously in 1836 in a French publication by Hôtel-Dieu de Paris. The procedure he described was a minimally invasive needle procedure. Because of high recurrence rates, new surgical techniques were introduced, such as fasciectomy and then dermofasciectomy. Most of the diseased tissue is removed with these procedures.Recurrence rates are low. For some individuals, the partial insertion of "K-wires" into either the DIP or PIP joint of the affected digit for a period of a least 21 days to fuse the joint is the only way to halt the disease's progress. After removal of the wires, the joint is fixed into flexion, which is considered preferable to fusion at extension. Research using large datasets in the UK has shown surgery to be safe and effective. When surgery needs to be repeated, however, the research suggests there are higher risks of serious complications such as finger amputation. Amputation of fingers may be needed for severe or recurrent cases or after surgical complications.
Sources: en.wikipedia.org
Cardarine is a common name for the investigational compound GW501516. It acts as a PPARδ agonist and is not approved for human use. It is prohibited in sport.
It activates PPARδ, a nuclear receptor that influences gene expression related to lipid and energy metabolism. Animal studies show changes in endurance and lipid levels. Human effects and risks are not well established.
No, cardarine is not a steroid. It belongs to a different chemical class, the PPARδ agonists. It is also not a selective androgen receptor modulator.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.